suspend coverag
reason report
new day array initi arri outperform pt
bottom line initi coverag array biopharma
arri outperform rate price target array
biopharma leader discoveri develop target
small molecul drug particular focu oncolog compani
world-class medicin chemistri platform produc multipl market
promis late-stag clinic asset mani approach
value-cr mileston royalti revenu stream array via
partnership see braftovi encorafenib braf inhibitor
mektovi binimetinib mek inhibitor best-in-class combin
launch global market accord compani report
treatment braf melanoma near-term potenti expand
braf colorect cancer limit competit see
favor catalyst path share believ arri
well-posit benefit recent resurg
launch best-in-class braf/mek inhibitor combin
braf melanoma see upsid consensu array
lead commerci asset braftovi braf inhibitor mektovi mek
inhibitor approv fda treatment braf mutant
melanoma june first quarter launch sale significantli
exceed expect though believ investor question
launch trajectori given entrench natur novarti nv nr
compet braf/mek combin see braftovi/mektovi best-
in-class target regimen treat braf melanoma base
profil demonstr phase columbu trial show
remark surviv benefit improv safety/toler rel
compet combin novarti roch earli sign patient
switch novarti combin braftovi/mektovi switch
dynam rel uniqu world oncolog treatment
bolster enthusiasm forecast consensu revenu
launch base patient-driven prescript model
captur naiv switch patient share dynam see peak us
sale
see high probabl success braftovi/mektovi braf
colorect cancer array conduct phase beacon
trial evalu combin braftovi/mektovi erbitux
treatment relapsed/refractori braf mutant area
extrem high unmet medic need base evalu
avail clinic preclin data see high probabl
success ahead anticip interim analysi expect
approv braftovi/mektovi would first-in-class
opportun limit competit horizon see
us revenu opportun repres
compani inform svb leerink llc research
revenu mm ep
net debt total capit
share outstand mil
year price history/av daili volume mil arri
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
fundament valu well fuel arri engin product
compani prolif target drug discoveri engin array
partner program mani collabor partner asset
variou stage develop addit ex-u royalti braftovi/
mektovi explicitli model royalti five array partner
program well potenti clinic regulatori
commerci mileston appli individu probabl success
royalties/mileston see risk-adjust valu
collabor per share approxim arri
arri well-posit benefit resurg target
oncolog sinc begin decemb three sizabl deal
target oncolog space signal resurg
valid signific valu interest target oncolog
space proven track record target small molecul drug
develop includ three four program nr
acquir via loxo oncolog loxo mp deal trk ret fgfr
see array biopharma medicin chemistri platform strateg
valuabl anticip arri share continu benefit
favor near-term catalyst path see
follow near-term catalyst arri includ earn
earli feb top-line data beacon interim analysi
updat data beacon safeti lead-in sli cohort
releas prior offici present januari american
societi clinic oncolog gastrointestin cancer symposium
gi provid increas confid top-line readout given median
progress free surviv mpf month newli matur
median overal surviv os month meaning
exceed activ either chemo/egfr braf triplet compar
model consensu revenu earn earli
februari high probabl success interim readout
beacon trial
posit near-term driver melanoma launch label
expans valu partner program
initi outperform rate price target
world-class medicin chemistri platform target oncolog grow
array biopharma commercial-stag biotechnolog compani two approv product
braftovi braf inhibitor mektovi mek inhibitor launch use combin
treatment braf-mut melanoma histor compani strong medicin chemistri
platform made array partner choic among broader biotechnolog sector lead
develop numer regist late-stag promis early-stag asset
launch braftovi mektovi juli see array biopharma compani undergo
posit transform fully-integr biotechnolog compani see multipl near-term
commerci clinic regulatori catalyst well substanti valu compani
partner pipelin strateg valu small molecul drug discoveri platform
compel reason arri share
strong launch braftovi/mektovi melanoma support best-in-class efficaci
safeti toler profil array braftovi mektovi receiv fda approv june
result initi launch quarter strong meaning exceed sell-
side expect earli launch feedback suggest strong uptak driven
treatment-nav patient well patient switch braf/mek combin
therapi believ due braftovi/mektovi strong pivot data phase
columbu trial suggest best-in-class efficaci well favor
safety/toler compar braf/mek regimen specif cross-trial
comparison braftovi/mektovi appear superior surviv metric median
month ahead month achiev compet regimen respect
pivot studi strike view differ overal surviv patient
columbu trial achiev month vs month roch zelboraf/cotel
month novarti tafinlar/mekinist pivot studi acknowledg
difficulti cross-trial comparison given consist perform zelboraf compar
arm trial believ data reason suggest true surviv advantag even
precis magnitud impli pivot dataset
overal surviv braf/mek doublet pivot trial
compani report svb leerink research
also importantli braftovi/mektovi regimen demonstr lower rate key advers event
significantli reduc toler durat exposur regimen
tafinlar/mekinist associ high rate fever recur frequent
difficult manag fever key sourc dose reduct treatment
discontinu columbu braftovi/mektovi patient present pyrexia
rel low grade case vs observ patient tafinlar/mekinist
grade case braftovi/mektovi also demonstr lower rate diarrhea
photosensit key emerg zelboraf/cotel see braftovi/mektovi
consider toler regimen superior surviv outcom believ drive
adopt extend treatment durat best-in-class profil drive long-term forecast
braf melanoma see peak revenu
see upsid launch consensu base patient-driven script model account
uniqu switch dynam follow strong initi launch quarter manag provid
increment color suggest substanti portion demand quarter
driven patient switch braf/mek therapi driven predominantli
toler issu seen tafinlar/mekinist pyrexia zelboraf/cotel diarrhea
photosensit treatment-experienc patient may
receiv braf/mek therapi mani month mani could later cours
diseas would anticip shorter treatment durat rel braf/mek nave
patient start therapi
forecast driven monthli patient-driven prescript model consid
braf/mek nave switch melanoma patient base conserv assumpt
penetr treatment durat see meaning upsid estim
braftovi/mektovi patient-driven prescript model drive above-consensu
see high probabl success braftovi/mektovi label expans braf
array conduct phase beacon trial evalu braftovi/mektovi erbitux
treatment relapsed/refractori r/r braf-mut colorect cancer see high
probabl success trial base initi data safeti lead-in sli trial
appear highli favor compar histor perform standard care chemo/egfr
regimen use control trial sli trial triplet combin
braftovi/mektovi/erbitux demonstr object respons rate orr local
review median month median matur overal surviv month ci
reach encourag progress free surviv triplet regimen
far exce typic overal surviv seen chemo/egfr regimen seen recent r/r
although respons larger beacon trial may vari sli view result
lead-in artifact small patient number expect similar result confid
outcom base known biolog braf driver bypass/escap
mechan run egfr re-activ craf tripl inhibit
egfr/braf/mek clinic valid phase trial vectibix tafinlar
trametinib show superior respons compar doublet therapi howev believ
braftovi better control craf result clinic activ similar observ
beacon sli oppos result seen tafinlar
also note beacon regimen appear favor toler low rate
grade well low incid treatment discontinu columbu pivot
trial melanoma braftovi/mektovi also show toler profil featur lower incid
sever pyrexia diarrhea phototherapy/rash
associ compet braf inhibitor signific challeng toler report
literatur suggest braftovi potent inhibitor multipl raf isoform
also specif braf inhibitor may result improv toler profil
seen clinic
given total data seen date assign probabl success
braftovi/mektovi braf ahead interim analysi expect could lead
supplement new drug applic snda submiss acceler approv
commerci braf attract opportun first approv braf/mek
combo contrast braf melanoma market braftovi/mektovi third
braf/mek combin enter market expect array meaning benefit first-in-
class potenti lack competit braf anticip posit interim data
lead snda submiss enabl potenti commerci launch given
high unmet medic need r/r braf patient rel lack competit
braf/mek combin model strong uptak braftovi/mektovi reach eventu
peak penetr second third line opportun model us sale
opportun account per share risk-adjust npv model
approxim valuat
notabl compani also conduct phase singl arm anchor trial
braftovi/mektovi/erbitux treatment-nav braf metastat trial expect enrol
patient braf mcrc prior therapi evalu orr
primari endpoint key secondari endpoint includ durat respons time respons
os compani believ anchor explicitli registr may
provid data could allow expans treatment-nav set either
regulatori label expans compendia list depend strength data
current model penetr set view upsid
array also well-posit benefit resurg target oncolog sinc
begin decemb seen three larg transact target oncolog
space glaxosmithklin buy tesaro tsro mp bristol-my buy celgen
celg mp buy loxo oncolog see deal
valid signific valu interest target oncolog space see array
extrem well-posit benefit notabl loxo oncolog deal driven primarili
valu trk program ret preclin fgfr program asset
origin develop collabor array see array world-class chemistri platform
differenti loxo deal particularli valid array small molecul drug
discoveri expertis believ array could provid signific strateg valu acquir
look bolster presenc target oncolog
also note compani well-capit cash equival
end septemb grow revenu melanoma launch partner
program see compani work posit capit strength strateg
flexibl renew focu deliv least one new wholly-own oncology-focus
ind clinic year would surpris see strateg interest
partner program underappreci provid fundament valu per share
model well fuel proprietari pipelin develop product
compani prolif drug discoveri engin array partner program less
collabor partner asset variou stage develop rang
approval/commerci preclin acknowledg investor may
difficulti ascrib valu partnership given breadth program
uncertainti around probabl success commerci uptak econom arri
arri valuat explicitli model royalti revenu six array partner
includ risk-adjust npv royalti stream model
potenti clinic regulatori commerci mileston total potenti valu
assign estim time probabl achiev includ risk-
adjust vale total see approxim per share total arri
valuat risk-adjust fundament valu royalti stream mileston payment
favor catalyst path drive arri share higher near-term catalyst arri includ
earn earli feb top-line data beacon interim analysi
updat data beacon sli cohort releas prior offici present
januari gi increas confid top-line readout given mpf
month newli matur mo month meaning exceed activ
either chemo/egfr braf triplet compar model above-consensu revenu
earn earli februari high probabl success interim readout
beacon trial
could wrong braftovi/mektovi launch melanoma
strong model prescript suggest upsid current consensu
possibl initi demand repres larger bolu switch patient remain
therapi result plateau revenu base analysi clinic preclin
data braftovi/mektovi braf colorect cancer believ beacon interim
readout like posit howev three arm trial perform
anticip lower treatment effect and/or higher placebo effect possibl trial could
fail final see signific valu array numer partner program
acknowledg program difficult investor valu
compani report svb leerink research
pt includ us revenu braftovi/mektovi braf melanoma colorect cancer
royalti partner pierr fabr ex-u sale
braf/mek combin well royalti mileston collabor partner loxo
oncolog trk ret program astrazeneca azn nr selumetinib
op tucatinib asln mp varlitinib also includ
risk-adjust npv array wholly-own pipelin drug discoveri
productpeak revenu mn phase developmentnpv arri mn probabl successrisk-adjust npv mn expect launchnet current valu share us braftovi/mektovi braf braftovi/mektovi braf melanoma braftovi/mektovi braf braftovi/mekatovi braf trk program ww ret program ww selumetinib ww tucatinib ww varltinib ww mileston dev pipelin drug discoveri asset fulli dilut share count risk-adjust equiti valu risk biopharma braftovi/mektovi braf melanomarow braftovi/mektovi braf melanoma royaltiesu braftovi/mektovi braf braftovi/mekatovi braf royaltiesloxo trk program ww royaltiesloxo ret program ww royaltiesazn selumetinib ww royaltiessgen tucatinib ww royaltiesasln varltinib ww royaltiescollabor mileston dev wholly-own pipelin drug discoveri platform array biopharma inc
braftovi/mektovi us revenu estim indic mn
braftovi/mektovi braf melanoma fda approv braftovi mektovi use
combin treat patient unresect metastat melanoma braf
mutat june drug launch juli report strong initi
net revenu launch quarter
forecast opportun use two distinct approach fy forecast
driven patient-driven prescript model contempl braf/mek nave
switch melanoma patient treatment-nav patient model braftovi/mektovi captur
share monthli incid braf melanoma patient group estim
patient per month per year assum monthli dropout rate guid larg
durat exposur columbu trial calcul number patient
remain therapi given month assum month treatment-
nave patient remain therapi estim believ conserv vs patient
exposur week arm
switch patient use tafinlar/mekinist sale calcul estim patient pool
patient estim would candid switch
braftovi/mektovi pool patient compris switch opportun model
monthli penetr rate braftovi/mektovi first three month gradual
ramp per month expect patient like switch would
experienc toler issu tafinlar/mekinist zelboraf/cotel would
expect initi bolu patient within first month switch gradual
declin patient alreadi expos braf/mek treatment vari
length time assum much aggress dropout rate patient receiv
less two month therapi discontinu treatment month four model net
monthli price per patient assum stabl gross-to-net adjust consist
estim approxim
visibl alpha consensu respect
braftovi/mektovi patient-driven prescript model drive above-consensu
revenu beyond util patient-bas incid model metastat melanoma
approxim melanoma contain mutat braf gene estim
annual incid braf melanoma patient diagnos treat grow
patient given clinic profil braftovi/mektovi suggest best-in-
class efficaci safety/toler anticip becom lead target therapi
combin treat braf melanoma patient conserv model real-world
durat month acknowledg upsid estim would like driven
primarili real-world durat close mirror columbu trial result mpf
month model assum annual price increas stabl gross-to-net
adjust forecast braftovi/mektovi sale
indic repres npv model repres arri
outsid canada array partner pierr fabr commerci
braftovi/mektovi europe/row commerci japan south
korea agreement includ substanti tier double-digit royalti rang
europe/row sale japan/south korea model ex-u
melanoma sale opportun percentag sale use ex-u sale
tafinlar/mekinist guid model peak royalti arri sale
relat braf melanoma result npv arri
braftovi/mektovi braf colorect cancer array evalu triplet combin
braftovi/mektovi erbitux treatment relapsed/refractori braf colorect cancer
on-going phase beacon trial base compel data gener
safeti lead-in sli portion trial fda grant combin breakthrough therapi
design btd august data sli compar favor histor
perform standard care chemo/egfr regimen set see high
likelihood success trial interim analysi anticip
contrast braf melanoma braftovi/mektovi third braf/mek combin
enter market expect array meaning benefit lack competit braf
follow posit interim data anticip array submit snda label
expans enabl potenti commerci launch given high unmet medic
need r/r braf patient rel lack competit braf/mek
combin model strong uptak braftovi/mektovi reach eventu peak
penetr opportun model sale given
strength data present date assign probabl success combin
result risk-adjust npv arri
notabl compani also conduct phase singl arm anchor trial
braftovi/mektovi/erbitux treatment-nav braf metastat trial expect enrol
patient braf mcrc prior therapi evalu orr
primari endpoint key secondari endpoint includ durat respons time respons
os compani believ anchor explicitli registr may
provid data could allow expans treatment-nav set either
regulatori label expans compendia list depend strength data
current model penetr set view upsid
see rapid uptak braftovi/mektovi r/r braf
outsid expect array partner benefit similar first-mov advantag
braf importantli partner provid global develop co-fund pierr
fabr fund global cost fund develop
cost model peak royalti array assign probabl success
result risk-adjust npv per share arri
collabor partner royalti owe compani prolif small molecul drug
discoveri world-class medicin chemistri array partner program twelv
compani includ sever promis late-stag program near commerci
detail partner program found partner program potenti
royalti mileston later report
addit ex-u royalti braftovi/mektovi melanoma select
model revenu five array partner program includ loxo oncolog lilli
trk program asset vitrakvi loxo ret inhibitor
astrazeneca selumetinib mek inhibitor tucatinib inhibitor
aslan asln mp cover colleagu jonathan chang ph cfa pan-her varlitinib
includ risk-adjust npv royalti stream arri valuat see
greatest valu come loxo/lilli program vitrakvi launch repres per
share risk-adjust npv model notabl program larg clinic de-risk
vitrakvi receiv fda approv novemb produc compel
phase data treatment ret-driven malign asset primari
valu driver recent acquisit loxo billion deal believ valid
qualiti asset produc arri well forecast commerci uptak
model ww peak sale trk result
royalti arri
also includ astrazeneca selumetinib inhibitor develop
treatment neurofibromatosi type pivot phase data present
american societi clinic oncolog azn expect file nda
registr see peak royalti program assign
probabl success result risk-adjust npv per share arri
includ two addit program tucatinib aslan pharma
varlitinib pivot data expect near-term sgen pivot trial
metastat breast cancer recent complet enrol first patient need
primari endpoint analysi anticip top-lin data later pivot data
also anticip asln varlitinib biliari tract cancer could enabl potenti
commerci risk-adjust program meaning result combin
npv arri valuat array partner program provid
underappreci valu wholly-own pipelin section report
addit detail program
collabor mileston array partner program array prolif medicin chemistri
platform produc numer drug develop candid mani out-
licens collabor partner june compani receiv total
research fund up-front mileston payment collabor partner
allow compani maintain research discoveri engin
note investor histor difficulti place valu around collabor
agreement mileston believ may especi case array given
number clinical-stag partnership howev exist partner program capabl
provid addit mileston payment june built detail
model account mileston least visibl
model contempl clinic develop regulatori commerci mileston
drug drug combin span seven array partnership
visibl includ partnership pierr fabr ono braftovi/mektovi loxo
oncolog trk program ret fgfr program
astrazeneca/merck selumetinib varlitinib roch
ipatasertib base regulatori file array collabor partner estim
time size individu mileston event risk-adjust assign
probabl achiev mileston discount anticip risk-adjust cash
flow use assum discount rate result risk-adjust npv mileston
base methodolog calcul total risk-adjust npv approxim
valuat total impact individu risk-adjust signific
aggreg note anticip mileston achiev estim
time-frame risk-adjust npv would approxim
consid approxim total mileston impli anoth
mileston payment limit visibl includ model
wholly-own pipelin drug discoveri engin histor array drug develop
engin excel produc laundri list tailor small-molecul major
partner howev addit encorafenib binimetinib compani current
hold world-wide right intern develop molecul inhibitor lmna-
relat dilat cardiomyopathi dcm evalu combin
keytruda expans cohort pancreat cancer platinum-refractori
ovarian cancer patient solid tumor progress prior therapi
importantli compani also intend advanc least one new oncolog agent clinic
per year go forward explicitli model
acknowledg difficult valu drug discoveri platform believ substanti
valu fundament strateg product discoveri engin array
includ risk-adjust npv per share account array wholly-own
pipelin small molecul drug discoveri platform
arri risk-adjust npv program/ind
valuat methodolog use risk-adjust sum-of-the-part methodolog valu array
biopharma examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens use wacc termin valu
nopat indic depend length patent protect account
valu beyond add cash requir invest
risk valuat
 commerci risk array launch two product braftovi mektovi
treatment braf melanoma repres compani first commerci
product failur meet exceed sale expect repres risk
 clinic risk array number on-going trial develop candid
includ encorafenib binimetinib trial produc
clinic data disappoint rel investor expect repres risk
 competit drug compet array could produc superl clinic
data lead increas competit market less-than-anticip uptak
arri product repres risk current valuat
program catalyst
braftovi/mektovi braf melanoma
melanoma fifth common cancer us new case
death diseas expect seer data approxim patient
advanc melanoma harbor activ mutat braf intracellular signal kinas
braf valin glutamin substitut codon serine-threonin kinas
braf commonli report braf mutat braf valin lysin
substitut less common braf inhibitor previous shown singl agent respons rate
clinic trial treatment-nav braf melanoma mpf around
month although singl agent inhibitor effect combin therapi inhibitor
mek downstream kinas produc significantli better clinic outcom term
orr os
array braftovi encorafenib oral select adenosin triphosph atp competit
inhibitor raf isoform includ braf craf potent inhibit clinic relev
braf mutat mektovi binimetinib oral select atp-uncompetit
inhibitor fda approv braftovi mektovi treatment brafm
melanoma june base result phase columbu trial
braf/mek inhibitor doublet alreadi approv use novarti tafinlar dabrafenib
mekinist trametinib zelboraf vemurafenib cotel cobimetinib
phase columbu studi two-part trial evalu activ braftovi/mektovi
vs braftovi monotherapi vs zelboraf monotherapi local advanc unresect metastat
melanoma patient harbor braf mutat part trial main pivot studi
enrol patient doublet braftovi qd/mektovi bid
arm monotherapi braftovi qd monotherapi zelboraf bid
primari endpoint trial assess blind independ review
arm vs zelboraf arm secondari analys includ vs
os patient report outcom
comparison arm perform demonstr
dual braf/mek inhibit superior singl agent braf inhibit although alreadi
clinic valid concept analysi necessari satisfi fda combin rule
requir demonstr agent regimen contribut activ decis dose
braftovi differ singl agent qd combin qd confound
comparison though necessit part trial part columbu patient
random receiv braftovi qd/mektovi bid braftovi monotherapi
columbu trial succeed primari key secondari endpoint part
part trial part trial last updat subsequ public
lancet oncolog os data present dummer et al lancet oncol
combin braftovi/mektovi significantli extend compar zelboraf monotherapi
vs braftovi monotherapi hr
vs part trial significantli extend
compar singl agent braftovi demonstr addit benefit inclus mektovi
interestingli mpf arm slightli shorter found
part vs suggest benefit higher braftovi dose
braftovi/mektovi combo braftovi monotherapi outperform zelboraf monotherapi
object respons durabl respons
primari progress free surviv analysi columbu part
importantli columbu also demonstr robust advantag overal surviv os median
os arm compar zelboraf monotherapi arm
singl agent braftovi group also extend surviv rel
zelboraf
treatment braftovi/mektovi toler lower rate grade either
singl agent braf inhibitor use trial time primari analysi data cutoff
present societi melanoma research patient
arm discontinu treatment compar braftovi zelboraf
monotherapi arm primari caus discontinu arm progress diseas
discontinu due ae occur patient braftovi
monotherapi patient zelboraf patient discontinu due physician patient
decis occur similar rate formal adjud ae relat approxim
doubl event occur singl agent brafi arm compar arm
treatment death occur patient patient
zelboraf patient dose reduct due occur
braftovi zelboraf patient respect similar trend seen dose interrupt
higher rate respect importantli rate grade
lower arm seen either braftovi zelboraf arm
addit lower overal rate patient longer median time first
grade time ae relat discontinu
delay grade ae relat discontinu patient
note focu safeti event time primari analysi event report
cumul evolv extend durat therefor ae rate grow time due
cumul toxic confound therapeut comparison activ toler
regimen enabl patient prolong treatment durat
columbu result suggest best-in-class efficaci toler result
columbu program compel suggest braftovi/mektovi combo could
differenti activ safeti key given late market entri third approv
cross trial comparison braftovi/mektovi appear surviv metric superior rest
class mpf braftovi/mektovi come ahead achiev
zelboraf/cotel cobrim seen tafinlar/mekinist two pivot studi
differ pale comparison appar advantag braftovi/mektovi os
patient median surviv mo zelboraf/cotel
tafinlar/mekinist although acknowledg limit cross trial
comparison magnitud differ braftovi/mektovi competitor
particularli os rang compel given consist perform
zelboraf compar trial believ reason like
braftovi/mektovi surviv advantag real precis magnitud impli
overal surviv braf/mek doublet pivot trial
compani report svb leerink research
importantli braftovi/mektovi regimen lower rate key significantli reduc
toler durat exposur regimen tafinlar mekinist
associ high rate fever recur frequent difficult manag
fever key sourc dose reduct treatment discontinu per tafinlar label
pyrexia observ patient tafinlar/mekinist grade case
columbu braftovi/mektovi patient present pyrexia rel low
signal seen zelboraf cotel diarrhea overal grade
photosensit occur patient grade photosensit reaction
consist persist rash resolv infrequ patient experienc grade reaction
blister sunburn-lik rash skin surfac braftovi mektovi
significantli lower rate reaction patient experienc diarrhea
grade photosensit seen patient experienc
base part data see braftovi/mektovi consider toler regimen
superior surviv outcom believ drive adopt extend treatment
braf/mek market dynam prescript data company-report revenu
market braf/mek inhibitor consist three combin novarti tafinlar/mekinist
roch zelboraf/cotel array braftovi/mektovi global market drug
current accord compani report annual basi consist
 revenu ex-u
roch zelboraf first braf inhibitor approv fda monotherapi
treatment patient unresect metastat melanoma braf mutat
zelboraf primari target treatment braf melanoma patient
world-wide zelboraf sale peak global revenu howev
follow fda approv glaxosmithklin braf inhibitor tafinlar mek inhibitor mekinist
monotherapi subsequ approv combin therapi earli
zelboraf quickli cede share braf/mek combin roch obtain approv
braf/mek combin zelboraf/cotel novemb tafinlar/mekinist
combin market novarti remain current market leader
iqvia prescript audit sale data appear captur braf/mek
combin sale entireti believ report sale data use
illustr histor market share dynam
tafinlar/mekinist assum role market leader follow combin approv
prescript sale data iqvia symphoni health appear reason captur
tafinlar/mekinist volum captur rate three recent quarter consist around
compar company-report us net revenu new drug launch
anticip volatil weekli monthli audit braftovi/mektovi caution
investor overreli data sourc initi quarter launch
analysi iqvia symphoni health data appear iqvia less reflect
initi quarter volum symphoni array report net revenu base
prescript integr sale suggest data may
repres demand rel iqvia data report approx prescript
project sale continu monitor weekli monthli
prescription/sal trend data aggreg
array support cooper group investig sponsor trial part life cycl
manag strategi braftovi mektovi trial design provid data
integr target therapi immune-oncolog io agent melanoma despit
domin role io melanoma target therapi still recommend frontlin option
patient harbor braf mutat prefer case rapid respons
clinic necessari howev ideal method sequenc combin target
immunotherapi unknown
secombit trial cooper group trial evalu optimum
sequenc approach braftovi/mektovi i/o opdivo/yervoy brafm melanoma patient
trial plan enrol brafm melanoma patient random three differ
treatment sequenc braftovi/mektovi progress follow opdivo/yervoy
opdivo/yervoy progress follow braftovi/mektovi two cycl braftovi/mektovi
follow opdivo/yervoy progress second administr
braftovi/mektovi primari endpoint trial overal surviv os progress free
surviv secondari endpoint studi primari complet date april
immu-target phase investig sponsor trial evalu tripl
combin keytruda braf melanoma first phase design determin
safeti toler triplet regimen contain keytruda braftovi mektovi
establish recommend phase dose phase portion patient enrol
receiv limit durat month cours triplet therapi month treatment
patient random continu triplet receiv keytruda monotherapi
primari endpoint trial secondari endpoint includ safeti os orr
trial plan enrol brafm melanoma patient primari complet date march
beacon phase trial braf-mut colorect cancer
metastat colorect cancer colorect cancer repres total us cancer
diagnos make indic common cancer diagnosi seer data
estim incid colon cancer incid rectal cancer
metastat diseas develop case liver primari site
metastat spread seer data nccn metastat patient present
unresect liver tumor liver metastas found time primari
tumor synchron associ wors prognosi greater diseas
dissemin incid mortal fallen larg part due broader
screen result earlier diagnosi includ identifi pre-cancer lesion
malign develop improv therapi
manag colorect cancer manag surgic resect possibl
chemoradi varieti chemotherapi regimen employ neo-adjuv set
improv resect adjuv therapi follow surgeri chemotherapi also play
signific role manag metastat diseas
egfr inhibit varieti target agent includ avastin inhibitor epiderm growth
factor receptor egfr particularli monoclon antibodi erbitux vectibix use
combin chemo well singl agent respons egfr inhibit particularli
depend anatomi molecular patholog diseas prognost
valu import make treatment decis
patient right-sid cecum hepat flexur primari tumor fail respond egfr
inhibit shorter egfri treat patient left side tumor
patient right side tumor perform wors treat egfr inhibitor vegf
inhibitor addit either avastin erbitux frontlin chemo folfiri
test phase calgb/swog trial found differ os
ra wild type patient overal venook et al jama median os
erbitux treat patient left-sid tumor vs right-sid tumor
importantli patient right-sid tumor greater surviv treat avastin mo
venook et al journal clinic oncolog may
although unclear molecular differ may underli anatom respons
pattern egfr inhibit recommend initi treatment left-sid tumor nation
comprehens cancer network nccn guidelin includ egfr inhibitor option
subsequ therapi right-sid tumor howev earli data suggest poorer respons later
line therapi well
over-express egfr hallmark seen estim tumor
nccn howev case respons anti-egfr therapi result
egfr test predict respons treatment guidelin discourag use
make treatment decis activ mutat downstream egfr
ras/raf/mek/erk pathway play import role ablat respons egfr-bas
treatment ra mutant patient treat regimen contain egfr inhibitor
under-perform compar receiv combo therapi activ compar
avastin trial placebo experi suggest inferior detriment
activ due addit toxic meaning benefit neither erbitux vectibix
approv use patient ra mutat either kra nra ra mutat
statu unknown activ mutat kra exon found roughli
patient addit patient kra nra mutat render
braf braf mutat tumor driver well known promin role
melanoma inhibitor mutat approv melanoma combin mek
inhibitor downstream braf patient harbor braf
mutat similar activ mutat ra respons egfr inhibit braf
mutat tend associ right-sid primari tumor elderli femal
patient high grade tumor
contrast melanoma braf mutant rel unrespons singl agent
treatment braf inhibitor zelboraf tafinlar mechanist work demonstr
egfr bypass braf inhibit activ craf parallel pathway
mek erk activ achiev corcoran et al cancer discov march
similarli inhibit braf shown upregul egfr like provid feedback
mechan bypass parallel activ akt signal could maintain
cellular prolifer prahallad natur jan meanwhil inhibit
egfr mutant braf reduc activ primari resist pathway lead
pre-clin tumor regress
dual inhibit egfr braf test phase swog trial
trial random patient ra wild type egfr inhibitor nave
braf mutant receiv irinotecan erbitux without zelboraf addit
braf inhibit extend increas object respons rate orr
zelboraf group vs month control orr vs
interestingli control patient crossed-ov zelboraf regimen
progress appear deriv clinic benefit mpf crossov
zelboraf combin erbitux irinotecan recommend option egfr inhibitor
nave ra wild type patient braf mutat
array novarti conduct phase trial examin combin erbitux braftovi
triplet also includ inhibitor alpelisib result present
tabernero et al orr erbitux/braftovi arm
patient stabl diseas median durat respons arm
triplet arm orr mdor stabl diseas mpf
alpelisib arm compar doublet hr arm mo
triplet modestli better vs doublet howev curv cross
hr surviv indic elev risk death triplet arm patient tripl
regimen experienc frequent tox without appar benefit given modest
advantag lack improv os
novarti conduct phase trial test combin tafinlar braf
inhibitor mekinist mek inhibitor vectibix egfr inhibitor cancer discov
triplet regimen produc orr stabl
diseas confirm respons mekinist/vectibix arm
patient stabl diseas confirm orr tafinlar/vectibix arm
patient achiev stabl diseas includ unconfirm respons
orr regimen would rise respect triplet
mekinist tafinlar doublet mdor tafinlar arm tripl combo
mpf two doublet arm tafinlar mekinist group
respect despit improv orr mpf patient triplet modestli
better doublet therapi note data similar report activ
tafinlar/mekinist doublet orr mpf similar patient corcoran et
respons egfr/mapk regimen
grade similar triplet arm mekinist doublet higher tafinlar
doublet similarli discontinu dose reduct dose delay similar triplet
arm mekinist doublet higher tafinlar arm data suggest signific
amount toxic contribut mekinist without contribut much benefit move
tripl combo margin harm toler addit tafinlar mitig mek
preclin data suggest braftovi could differenti despit lack activ
mekinist arm triplet therapi demonstr synergist benefit notwithstand data
indic altern pathway akt also activ data suggest
effect blockad mapk pathway protein could improv respons patient given
craf propos role bypass braf inhibit therapi potent inhibit craf may
contribut increas respons rate extend durabl diseas control respons
inhibit craf current market braf inhibitor vari consider may provid
insight clinic respons date well guid treatment select futur braftovi
select inhibitor raf isoform sub-nm potenc includ driver mutat braf
wild type braf craf accord label braftovi biochem
braf wild type braf wild type craf equal
import sub-nm potenc view equi-pot braftovi inhibit
braf isoform craf mean clinic relev craf inhibit like
obtain clinic dose
per prescrib inform tafinlar also highli potent inhibitor mutant braf
mutat tafinlar also inhibit
wild type braf craf although tafinlar craf
repres potent activ view believ drop potenc rel mutat
braf isoform signific suggest sub-optim inhibit may result clinic relev
dose narrow therapeut window dose reduct necessari label
zelboraf contain data howev report literatur suggest gener
weaker wild type raf inhibitor tafinlar drop activ braf
craf peng et al cancer cell although limit extrapol
pre-clin activ measur least compar data lead us believ
braftovi may activ braf inhibitor
beacon clinic program array advanc braftovi mektovi
beacon program braftovi mektovi combin erbitux receiv fda
breakthrough therapi design btd treatment braf metastat
failur one two prior line therapi base preliminari result beacon
phase beacon trial design studi combin mapk
pathway inhibit egfr blockad patient r/r braf mutant trial
recent complet enrol announc competitor confer patient
random receiv standard care folfiri irinotecan chemo erbitux doublet
contain braftovi erbitux triplet regiment braftovi mektovi erbitux enrol
open patient receiv prior regimen howev patient prior
therapi limit enrol
primari endpoint trial overal surviv triplet arm compar control
secondari endpoint includ os doublet compar control os triplet
compar doublet orr durat respons
base regulatori feedback array amend trial design incorpor interim analysi
orr durat respons expect occur success interim analysi
would enabl array file snda acceler approv trial open label would
expect regul review preliminari os data part file
safeti lead-in includ beacon design patient lead-in trial assess
safeti toler braftovi/mektovi/erbitux regimen safeti lead-in sli includ
patient enrol dose-determin cohort dose expans select dose
braftovi administ qd mektovi bid erbitux initi
follow qw
patient enrol cohort braf mutant metastat progress
follow prior therapi patient time enrol
receiv prior irinotecan patient need eastern cooper oncolog
group ecog patient right side primari tumor
left side primari tumor common site metastas liver
lymph node patient metastat diseas organ
one patient braf mutat exclud efficaci analys due violat
inclus criteria
trial result updat week ahead gi present januari kopetz et
al gi septemb datacut patient
discontinu primarili due progress diseas one patient discontinu due
one patient die trial remain on-going studi treatment
disposit unchang prior datacut present esmo gi
object respons seen impress evalu patient includ
local assess stabl diseas best respons two
patient evalu report esmo gi median durat respons
local assess respond maintain respons longer respons
stronger patient fewer prior therapi vs respect
last point import given phase portion beacon limit enrol heavili
pre-treat patient rel sli studi patient adjud respond base
local review determin evalu central review reduc orr
patient achiev patient achiev pr accord
central assess modest discrep orr local central review
uncommon notabl orr trial remain well excess publish compar even
accord stringent review median durat respons central review
report howev proport respond maintain respons month longer
median durat exposur trial two longest durat
on-going patient respond
beacon sli waterfal plot local central review
durat exposur segment therapi beacon sli
mpf cohort ci appar influenc line therapi
despit higher respons rate less pre-treat patient mpf patient
compar subset median os cohort reach
encourag rel expect surviv patient regimen
progress free surviv beacon sli
overal surviv beacon sli
treatment triplet regimen gener well toler patient experienc
grade howev rate individu event low common fatigu
anemia increas creatin kinas increas ast urinari tract
infect discontinu least one drug cocktail due
interrupt chang dose least drug patient die treatment
within day stop treatment treatment death due diseas progress
expect beacon succeed activ braftovi mektovi erbitux regimen sli trial
appear highli favor compar histor perform standard care chemo/egfr
regimen irinotecan erbitux well similar doublet triplet regimen featur
egfr mapk pathway inhibitor
activ compar arm beacon trial either irinotecan folfiri chemo
erbitux irinotecan erbitux control arm phase swog trial
produc orr mpf egfri nave braf
patient although altern regimen beacon folfiri erbitux intens
still expect signific improv orr without inclus braf inhibit
primari tumor driver remain unaddress beacon sli cohort orr
local review mpf mo view unreach
compar featur braf/mek inhibit certainli one without either
although respons larger beacon trial may vari sli view result
lead-in artifact small patient number expect similar result confid
outcom product known biolog braf driver bypass/escap
mechan run egfr re-activ craf tripl inhibit
egfr/braf/mek clinic valid phase trial vectibix tafinlar
trametinib show superior respons compar doublet therapi howev
believ braftovi better control craf result clinic activ similar observ
beacon sli oppos result seen tafinlar
importantli beacon regimen appear favor toler low rate grade
well low incid treatment discontinu columbu pivot trial
melanoma braftovi/mektovi also show toler profil featur lower incid
sever pyrexia diarrhea phototherapy/rash associ
compet braf inhibitor signific challeng toler report
literatur suggest although braftovi potent inhibitor multipl raf isoform
also specif braf inhibitor may result improv toler profil
seen clinic koelbling et al curr opin oncol
anchor trial braf anchor trial phase singl
arm trial braftovi/mektovi/erbitux treatment-nav brafm metastat braf
mcrc patient prior therapi metastat diseas enrol receiv
treatment progress unaccept toxic primari endpoint orr secondari
endpoint includ dor time respons os qualiti life safeti toler
pharmacokinet patient follow-up continu everi three month post-treat death
array view anchor possibl way expand braftovi/mektovi label line agnost
indic beacon pivot trial enrol patient although activ
frontlin like extrapol upcom beacon result without addit trial
data treatment-nav patient file make unlik fda would
grant indic beyond beacon enrol criteria array believ data anchor
list trial complet date june could use pursu label expans discuss
without separ control trial event regulatori agenc view anchor
suffici support line agnost approv expect trial would suffici amend
treatment guidelin nccn drive label use
array partner program provid underappreci valu
loxo oncolog trk ret fgfr
vitrakvi larotrectinib potent specif pan-trk inhibitor trk famili tropomyosin
receptor kinas receptor ligand neurotrophin famili trk
signal involv growth prolifer neuron precursor function
develop nervou system trk fusion implic driver mutat
sever tumor although low frequenc rariti tumor larg number
histolog identifi present challeng accur assess
incid trk fusion malign current estim wide recent loxo present
updat epidemiolog data suggest incid trk fusion malign rang
annual us rariti trk fusion tumor present uniqu
commerci challeng trk fusion appear concentr tumor type
unlik ret fusion limit experi treat physician identifi
loxo bayer partner commerci vitrakvi bayer respons
activ outsid loxo/bay co-promot drug particip profit-
split us market author applic vitrakvi submit august
committe medicin product human use chmp opinion anticip
design address resist mutat could emerg use vitrakvi
drug current evalu studi enrol progress
slowli initi anticip due longer-than-anticip durat respons
vitrakvi initi data phase portion studi expect present
recent project nda submiss potenti regulatori action
ret-driven malign select inhibitor ret kinas
identifi oncolog driver medullari papillari thyroid cancer mtc
well non-smal cell lung cancer nsclc ret form part receptor complex
gdnf glial deriv neurotroph factor famili ligand transduc signal cell
signal ret implic growth develop ret loss function
associ kidney defect hirschsprung diseas condit character lack
gi tract innerv result intestin misfunct damag
ret gain function abnorm includ varieti point mutat primari driver
mtc ret fusion promin nsclc ret fusion aris
chromosom rearrang join wild type ret kinas domain togeth varieti
partner fusion partner contain structur motif enabl ligand independ
dimer coil coil leucin zipper remain without normal control
dimer common activ step kinas caus self-phosphoryl chang
kinas domain activ conform ligand independ dimer
lead constitut rather regul activ unregul activ lead
abnorm cell prolifer cancer
data on-going phase basket trial shown impress respons
rate orr ret fusion mutant patient emerg profil continu
one high efficaci toler durabl note inform
last updat annual world lung meet septemb
receiv breakthrough therapi design btd fda septemb
treatment patient metastat ret-fusion-posit nsclc progress
follow platinum-bas chemo therapi patient ret-mut medullari
thyroid cancer mtc progress follow prior treatment accept
altern option addit btd design grant octob treatment
ret fusion thyroid cancer patient requir system therapi progress follow
prior treatment accept altern treatment option current guidanc suggest
nda file like potenti enabl approv commerci
model initi launch captur major share ret-fus
lung thyroid cancer peak result us revenu also see
potenti second-lin treatment ret inhibitor underappreci opportun
patient fail frontlin like receiv op
compet second line model assum frontlin ret patient
fail therapi eventu receiv treatment ret second line view
meaning opportun blueprint also see increment opportun
model second line peak revenu
tucatinib potent small molecul revers inhibitor low activ
egfr associ rash diarrhea seen tyrosin kinas inhibitor
tki obtain tucatinib via acquisit cascadian
tucatinib appear rel toler profil even combin low
rate grade diarrhea nausea hand-foot syndrom seen combin herceptin
capecitabin
tucatinib current studi on-going trial metastat
breast cancer evalu tucatinib combin herceptin capecitabin vs herceptin
capecitabin alon januari announc initi cohort patient
use primari analysi enrol full enrol patient
expect complet primari endpoint base blind independ central
review bicr secondari endpoint includ patient baselin brain met
overal surviv orr safeti believ data readout could possibl
posit pivot data potenti lead nda submiss
remain encourag tucatinib toxic profil specif lack diarrhea
demonstr date could strong differenti factor drug especi
accompani efficaci either monotherapi combin agent secondli
tucatinib shown promis potenti treatment patient brain metastas given
abil cross blood brain barrier bbb profil confirm on-going
trial see potenti signific threat puma mp nerlynx
also seek label expans metastat breast cancer
astrazeneca selumetinib meki neurofibromatosi type
astrazeneca current develop selumetinib oral select inhibitor
astrazeneca obtain exclus world-wide right develop commerci
selumetinib array term agreement array entitl potenti
mileston payment specif selumetinib well double-digit royalti
neurofibromatosi type autosom domin disord caus mutat
neurofibromin gene result tumor grow along nervou system throughout
bodi plexiform neurofibroma develop person
tumor cancer typic grow skin caus substanti
complic includ pain function impair disfigur
june result registr phase sprint trial present
sprint evalu patient plexiform neurofibroma treatment selumetinib
result overal respons rate result confirm respons rate
observ earlier studi like form basi file model
astrazeneca submit nda potenti enabl commerci
asln mp cover jonathan chang ph cfa
varlitinib oral revers small molecul pan-her inhibitor current develop
biliari tract cancer btc gastric cancer
aslan licens varlitinib array success complet five phase clinic
trial rang solid tumor januari aslan enter new licens agreement
array obtain exclus world-wide licens develop manufactur commerci
varlitinib human anim therapeut diagnost prophylact use
top-lin data trial varlitinib capecitabin biliari tract cancer btc
expect poster contain interim data phase trial varlitinib
gemcitabin cisplatin btc present gi symposium januari
companyprogram/drugtherapeut areaeventtimingev typetri phasearray biopharmabraftovi/mektovibraf data beacon safeti lead-in sli trial braf dataphiiiarray biopharmabraftovi/mektovibraf melanomacommerci launch updat braftovi/mektovi braf melanomaearli biopharmabraftovi/mektovibraf enrol phase beacon trial braf enrollmentphiiiloxo oncologyvitrakvitrk malignanciespotenti chmp opinion unresect metastat solid tumor biopharmabraftovi/mektovibraf melanomapdufa date braftovi/mektovi snda includ os data phase columbu oncologyvitrakvitrk malignanciespotenti ema approv ntrk-fusion biopharmabraftovi/mektovibraf analysi phase beacon trial braf look dataphiiiseattl metastat bcdata phase pivot trial dataphiiastrazenecaselumetinibneurofibromatosi type nda/maa pediatr plexiform malignanciesfil nda previous treat ret fusion solid tumor ret-mut thyroid cancerl biopharma array biopharma inc
array biopharma partner program potenti royalti mileston
partnerprogram drugstatusroyaltiesachiev milestonesoustand milestonespierr fabrebraftovi/mektovi eu eu approv braf melanomaeu phase braf crctier royalti start sale increas sale up-front ema approv totalup achiev commerci milestonesono pharmaceuticalbraftovi/mektovi jp jp approv braf melanomajp phase braf crcstart annual net sale billion increas annual net sale billion up-front two develop milestonesup regulatori milestonesup commerci milestonesvitrakvi trk vitrakvi approv usvitravkvi submit phase digit percentag ww net salesloxo made accru mileston payment dec laro respectivelywith respect trk product candid loxo requir pay mileston payment compound substanti major due upon achiev commerci ret phase registr mid singl digit percentag ww net develop mileston month end sept respect non trk target includ ret loxo requir pay array mileston payment substanti major due upon achiev commerci mileston fgfr programpreclinicalmid singl digit percentag ww net salesundisclosedacross program collabor trk ret fgfr remain devleop mileston achiev commerci milestonesseattl geneticstucatinib registr doubl digit up-front may up-front totaln/aaslan pharmaceuticalsvarlitinib pan-her phase digit royalti net salesiniti up-front payment develop regulatori milestonesup commerci milestonesastrazeneca/merckselumetinib mek phase registr doubl digit up-front mileston specif selumetinib develop kra phase up-front option exercis feesup remain develop mileston remain commerci mileston relat two drug compoundsasahi kasei pharma trka phase doubl digit up-front mileston paymentsup addit develop commerci milestonescelgenemotolimod tlr phase mileston paymentsup remain clinic commerci milestonesganovo danoprevir china hcvroyalti miletson paymentsup clinic commerci milestonesipatasertib akt phase up-front milestonesup develop clinic milestones lillyprexasertib clinic milestonesup clinic regulatori milestonesloxo oncologyroch genentech array biopharma inc
array biopharma mn
licens mileston revenu
partner program
sec file svb leerink estim
array biopharma balanc sheet flow mn
chang
oper
invest
financ
sec file svb leerink estim
